PMID: 7537561Jan 1, 1994Paper

Cellular pharmacology and protein binding of phosphoromonothioate and phosphorodithioate oligodeoxynucleotides: a comparative study

Antisense Research and Development
J TonkinsonC A Stein

Abstract

Phosphorodithioate (PS2) oligodeoxynucleotides (oligos) represent a relatively new class of backbone-modified oligo that have potential use as antisense agents. PS2 oligos are isoelectronic with phosphodiester (PO) and phosphoromonothioate (PS) oligos, and are nuclease resistant. However, unlike their PS congeners, PS2 oligos do not contain chiral centers. Little is known about the manner in which PS2 oligos interact with biological systems. In this study, we compare the cellular pharmacology of PS and PS2 oligos in HL60 cells. Cell surface binding, internalization, and compartmentalization are examined. Furthermore, the ability of PS and PS2 oligos to bind to rsCD4 and bFGF and to inhibit the activity of protein kinase C (PKC) is examined. Although the behavior of PS2 oligos closely parallels that of PS oligos, PS2 oligos appear to interact with some biological systems in a slightly different manner than PS oligos. These results indicate that PS2 oligos may have therapeutic potential other than as antisense agents.

References

Jul 1, 1978·Proceedings of the National Academy of Sciences of the United States of America·S Ohkuma, B Poole
Jul 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·W S MarshallM H Caruthers
Feb 15, 1990·The Biochemical Journal·S A RotenbergI B Weinstein
Sep 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·L A YakubovV V Vlassov
May 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·S L LokeL M Neckers
Apr 25, 1988·Nucleic Acids Research·C A SteinJ S Cohen
Nov 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·E J BowmanK Altendorf
Mar 12, 1993·Science·W S Marshall, M H Caruthers

❮ Previous
Next ❯

Citations

Aug 28, 2016·Nucleic Acids Research·N Dinuka AbeydeeraXianbin Yang
Oct 6, 1998·Annual Review of Biochemistry·S Verma, F Eckstein
Jul 14, 2000·Nucleosides, Nucleotides & Nucleic Acids·G TosquellasJ L Imbach
Dec 3, 2016·Current Protocols in Nucleic Acid Chemistry·Xinhui LouXianbin Yang
Aug 3, 2017·International Journal of Molecular Sciences·Shuaijian NiGe Zhang
May 23, 2002·Antisense & Nucleic Acid Drug Development·Jean-Charles BolognaFrançois Morvan
Jan 1, 1995·Antisense Research and Development·G TarrasónJ Piulats
Sep 2, 2016·Current Protocols in Nucleic Acid Chemistry·Xianbin Yang
Jul 13, 2001·Pharmacology & Therapeutics·C J Wraight, P J White

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.